AlphaCrest Capital Management LLC Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Posted by on Mar 9th, 2023

AlphaCrest Capital Management LLC lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 55.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,879 shares of the biotechnology company’s stock after selling 3,522 shares during the period. AlphaCrest Capital Management LLC’s holdings in United Therapeutics were worth $603,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Guardian Wealth Advisors LLC purchased a new stake in shares of United Therapeutics during the third quarter worth about $27,000. Ronald Blue Trust Inc. purchased a new stake in shares of United Therapeutics during the second quarter worth about $28,000. Neo Ivy Capital Management purchased a new stake in shares of United Therapeutics during the second quarter worth about $48,000. Quadrant Capital Group LLC increased its stake in shares of United Therapeutics by 51.0% during the second quarter. Quadrant Capital Group LLC now owns 225 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 76 shares in the last quarter. Finally, James Investment Research Inc. increased its stake in shares of United Therapeutics by 202.2% during the third quarter. James Investment Research Inc. now owns 269 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 180 shares in the last quarter. Hedge funds and other institutional investors own 95.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on UTHR. The Goldman Sachs Group began coverage on shares of United Therapeutics in a research note on Monday, December 5th. They set a “sell” rating and a $230.00 target price for the company. UBS Group began coverage on shares of United Therapeutics in a research report on Tuesday, December 6th. They set a “buy” rating and a $320.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $265.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 23rd. Morgan Stanley lowered their price target on shares of United Therapeutics from $330.00 to $320.00 and set an “overweight” rating on the stock in a research report on Thursday, February 23rd. Finally, LADENBURG THALM/SH SH lowered their price target on shares of United Therapeutics from $295.00 to $285.00 in a research report on Thursday, February 23rd. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $291.55.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 12,000 shares of the stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the completion of the transaction, the executive vice president now owns 36,397 shares of the company’s stock, valued at approximately $7,145,095.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Paul A. Mahon sold 12,000 shares of the stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the completion of the transaction, the executive vice president now owns 36,397 shares of the company’s stock, valued at approximately $7,145,095.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $279.27, for a total transaction of $2,234,160.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $36,305.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 200,720 shares of company stock valued at $51,622,626. Company insiders own 12.40% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $222.64 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.85 and a quick ratio of 9.55. The stock has a market cap of $10.31 billion, a price-to-earnings ratio of 14.82, a price-to-earnings-growth ratio of 1.74 and a beta of 0.62. The firm has a 50 day simple moving average of $257.67 and a 200-day simple moving average of $246.78. United Therapeutics Co. has a 1-year low of $158.38 and a 1-year high of $283.09.

United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its quarterly earnings data on Wednesday, February 22nd. The biotechnology company reported $2.67 earnings per share for the quarter, missing analysts’ consensus estimates of $4.12 by ($1.45). The company had revenue of $491.50 million for the quarter, compared to analysts’ expectations of $519.20 million. United Therapeutics had a return on equity of 16.30% and a net margin of 37.56%. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.35 EPS. On average, analysts expect that United Therapeutics Co. will post 18.08 EPS for the current year.

About United Therapeutics

(Get Rating)

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.

Read More

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.